Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

The Lancet

Volumn 372, Issue 9637, 2008, Pages 449-456

  Motzer, Robert J ^a   Escudier, Bernard ^b   Oudard, Stéphane ^c   Hutson, Thomas E ^d   Porta, Camillo ^e   Bracarda, Sergio ^f   Grünwald, Viktor ^g   Thompson, John A ^h   Figlin, Robert A ⁱ   Hollaender, Norbert ^j   Urbanowitz, Gladys ^j   Berg, William J ^j   Kay, Andrea ^j   Lebwohl, David ^j   Ravaud, Alain ^k  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^f Azienda Ospedaliera   (Italy)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h Seattle Cancer Center Alliance   (United States)

ⁱ CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^j NOVARTIS PHARMA AG   (Switzerland)

^k HÔPITAL SAINT ANDRÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; INTERFERON; INTERLEUKIN 2; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER SYSTEM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSPNEA; FATIGUE; FEMALE; HAZARD RATIO; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOPHOSPHATEMIA; INFECTION; INTERACTIVE VOICE RESPONSE SYSTEM; KIDNEY CARCINOMA; LEUKOPENIA; LUNG DISEASE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RASH; SCORING SYSTEM; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KARNOFSKY PERFORMANCE STATUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; SIROLIMUS;

EID: 48649107474     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61039-9     Document Type: Article

References (24)

1. Kaelin W.G. The von Hippel-Lindau tumor suppressor gene and kidney cancer. Clin Cancer Res 10 (2004) 6290-695S
2. Brugarolas J. Renal cell carcinoma-molecular pathways and therapies. N Engl J Med 356 (2007) 185-187
3. Brugarolas J.B., Vazquez F., Reddy A., Sellers W.R., and Kaelin W.G. TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell 4 (2003) 147-158
4. Thomas G.V., Tran C., Mellinghoff I.K., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 12 (2006) 122-127
5. Motzer R.J., Bander N.H., and Nanus D.M. Renal cell carcinoma. N Engl J Med 335 (1996) 865-875
6. Coppin C., Porzsolt F., Autenrieth M., Kumpf J., Coldman A., and Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 3 (2004) CD001425.
7. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med 356 (2007) 115-124
8. Escudier B., Eisen T., Stadler W.M., et al., for the TARGET Study Group. Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 356 (2007) 125-134
9. Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 356 (2007) 2271-2281
10. Escudier B., Pluzanska A., Korlewski P., et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370 (2007) 2103-2111
11. Coppin C., Le L., Porzsolt F., and Wilt T. Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev 2 (2008) CD006017.
12. Jac J., Giessinger S., Khan M., Willis J., Chiang S., and Amato R. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 25 18 suppl (2007) 261S
13. O'Donnell A., Faivre S., Burris H.A., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26 (2008) 1588-1595
14. Tabernero J., Rojo F., Calvo E., et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 26 (2008) 1603-1610
15. Tanaka C., O'Reilly T., Kovarik J.M., et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26 (2008) 1596-1602
16. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
17. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
18. Aaronson N.K., Ahmedzai A., Bergman B., et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85 (1993) 365-376
19. Cella D., Yount S., Brucker P.S., et al. Development and validation of a scale to measure disease-related symptoms of kidney cancer. Value Health 10 (2007) 285-293
20. Lan K.K.G., and DeMets D.L. Discrete sequential boundaries for clinical trials. Biometrika 70 (1983) 659-663
21. O'Brien P.C., and Fleming R.T. A multiple testing procedure for clinical trials. Biometrics 35 (1979) 549-556
22. Johnson J.R., Williams G., and Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21 (2003) 1404-1411
23. Amato R.J., Misellati A., Khan M., and Chiang S. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 24 18 suppl (2006) abstract 4530.
24. Atkins M.B., Hidalgo M., Stadler W.M., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918